The BTN3A2 Knockout SK-HEP-1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human SK-HEP-1 cell line. This product features targeted disruption of the BTN3A2 gene, which encodes a butyrophilin family member involved in immune regulation. As a polyclonal pool, the cell population contains a heterogeneous mix of edited alleles, providing a robust loss-of-function model for studying BTN3A2-dependent signaling without the bias of clonal selection. The knockout background enables researchers to interrogate the role of BTN3A2 in phosphoantigen sensing and T cell activation pathways.
The parental SK-HEP-1 cell line is a hepatic endothelial-like adenocarcinoma line originally established from the ascites of a patient with liver adenocarcinoma. These cells exhibit a unique endothelial-like phenotype, making them a valuable model for studying tumor?Cimmune interactions, particularly in the context of hepatocellular carcinoma and metastatic liver disease. The endothelial characteristics of SK-HEP-1 allow investigation of how BTN3A2-mediated signaling may influence immune cell recruitment and activation within the tumor microenvironment.
BTN3A2 is a transmembrane protein that forms a functional complex with BTN3A1 to sense phosphorylated non-peptide antigens (phosphoantigens) such as (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate (HMBPP) and isopentenyl pyrophosphate (IPP). Interaction with phosphoantigens triggers conformational changes in the BTN3A1-BTN3A2 complex, which is recognized by the T cell receptor (TCR) V??9V??2 on V??9V??2 T cells, leading to their activation. Downstream signaling involves PI3K-Akt and RhoB pathways, culminating in the secretion of interferon-?? (IFN-??) and tumor necrosis factor-?? (TNF-??) and the induction of cytotoxic responses against tumor cells. Cytokines and phosphoantigens serve as upstream regulators, while BTN3A3 can also contribute to the complex formation, modulating immune surveillance.
In SK-HEP-1 cells, BTN3A2 knockout disrupts the phosphoantigen-sensing machinery, impairing the ability of these tumor cells to stimulate V??9V??2 T cell-mediated cytotoxicity. This loss-of-function model is particularly relevant for dissecting immune evasion mechanisms in hepatic adenocarcinoma, where BTN3A2 expression may influence the efficacy of innate-like T cell responses. By eliminating BTN3A2, researchers can evaluate its contribution to tumor recognition and escape, providing insights into the development of phosphoantigen-based immunotherapies for liver cancers and other malignancies.
Typical applications include co-culture experiments with V??9V??2 T cells to measure T cell activation via flow cytometry (e.g., CD69, degranulation markers), phosphoantigen stimulation assays with ELISA-based quantification of IFN-?? and TNF-?? secretion, and cytotoxicity assays to assess tumor cell killing. Western blotting for phosphorylated Akt and RhoB can delineate signaling events downstream of BTN3A2 disruption. This polyclonal knockout model is a powerful tool for cancer immunotherapy research, infectious disease studies, and autoimmune disorder investigations. For additional information or custom requests, please contact Ascent Research.
